KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC
April 12th 2024Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.
Read More
Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC
March 8th 2024David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.
Read More
Triple Combination Therapies in RCC: Clinical Trial Insights
December 19th 2023Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
Read More
Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing
December 12th 2023Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
Read More
Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC
November 28th 2023Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.
Read More
Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification
October 30th 2023Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.
Read More